Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Younger generations need digital healthcare solutions. Hims' birth and ascent is a lesson in psychology. I disclose my original position of just under 50,000 shares at a cost basis of $5.50. I value Hims using a DCF and EPS table so investors will have a clear picture of my valuation and can calculate their own from my table.

Hims & Hers Health: A Lesson In Psychology

Global X Telemedicine & Digital Health ETF

LifeMD 

With the growing demand for telemedicine, the market could be worth about $450 billion by the time 2032 rolls around. That's according to Emergen Research.

3 Stocks That Could Benefit from the Rise of Telemedicine

Airbnb

Palo Alto Networks

In the dynamic market, certain stocks emerge as titans. They are disrupting traditional markets and hold meteoric growth potential.

3 Market-Disrupting Stocks Primed for a 400% Leap in the Next 2 Years

Eli Lilly

Novo Nordisk

Teladoc

Weightwatchers International Inc.

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.

Can WeightWatchers Regain Its Mojo after Oprah Steps Down?

Hims & Hers Health, Inc. has grown from a startup ($82m revenues in 2019) to a multi-billion-dollar company ($872m revenues in 2023) with more than 1.5 million subscribers; showcasing its scalability and product development. Hims & Hers Health achieved its first GAAP profitable quarter and provided strong 2024 guidance. Hims & Hers has improved its marketing efficiency, reducing the payback period for marketing expenses, demonstrating effective customer acquisition strategies.

Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that members of the company's management team will be participating in Canaccord Genuity's Virtual eCommerce Sustainable Advantage Forum on March 14, 2024. All events will be webcast live and archived on the Hims & Hers investor relations website at https://investors.forhims.com. About Hims & Hers Health, Inc. Hims & Hers is the lead.

Hims & Hers to Participate in Canaccord Genuity's Virtual eCommerce Sustainable Advantage Forum on March 14, 2024

Palantir Technologies

Snowflake

GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) saw their shares skyrocket in early 2021 after several Reddit users incited a rally. Investors may have largely lost interest in these two stocks.

3 Meme Stocks that r/WallStreetBets Loves (but Shouldn't!)

The telehealth industry isn't done expanding and there are some great deals now for growth-oriented investors. Teladoc Health is a top name in telehealth, generating more than $2.6 billion in revenue last year.

2 Telehealth Stocks to Buy Hand Over Fist in March

Ceragon Networks

Block

Unisys

Zeta Global Holdings Corp

Zymeworks Inc

In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the listed tech titans to emerge as veritable champions.

Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade

Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Hims & Hers Health, Inc. (HIMS) a Strong Momentum Stock: Buy Now?

Hims & Hers Inc. NYSE: HIMS is a telehealth platform in the medical sector that has turned the corner into GAAP profitability. The company got its start offering convenient, frictionless and discreet erectile dysfunction (ED) prescription solutions for men but has since expanded its offering into primary care and health and wellness products, including weight loss solutions for men and women.

Hims & Hers Stock Rises On Stimulating Earnings Growth

The shares of Hims & Hers Health (NYSE: HIMS), a direct-to-consumer telehealth company, have surged by more than 40% since the release of its Q4 earnings report and more than 50% since the start of the year.

Healthcare stock up 50% in 2024, and it might be just the beginning

Aehr Test Systems

Aspen Aerogels

Enovix Corporation

Jumia

Lithium Americas Argentina Corp

SoundHound AI Inc

Small-cap stocks haven't quite caught up to wider investor sentiment, but that trend is set to change. While large- and mega-caps like those within the S&P 500 survived and, in many cases, thrived, over the past year, small-cap indices like the S&P 600 underperformed — 26%+ and 5.5%, respectively.

The Top 7 Small-Cap Stocks to Buy in March 2024

Hims & Hers Health is up big on a blowout Q4 earnings report. The company is taking market share from competitors.

Hims & Hers Health Surges 30% After Earnings. Here Is Why the Stock Is Still a Magnificent Buy.

CVS Health

DexCom

While telehealth stocks, once stars of the pandemic era, have seen a recent dip in investor interest, savvy investors recognize the sector's bright future. Moreover, according to TalkSpace (NASDAQ: TALK ) CEO Jon Cohen, it could be argued that the pandemic catapulted telehealth forward by a decade, ushering in a new era of at-home primary and specialty care demanding investor attention.

3 Telehealth Stocks With Room to Run in 2024

Hims & Hers Health, Inc. (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge

Investing in healthcare stocks may not seem very exciting. This group of low-beta stocks serves as a defensive area of the consumer staples sector without much growth or activity.

This healthcare stock making a buzz with 160% growth

Shares of Shares of Hims & Hers Health popped Tuesday after the company reported better-than-expected quarterly results.

Hims & Hers soars 32% on rapid growth in mental health, weight loss and dermatology treatments

The company reported its first profitable quarter.

Is Hims & Hers Health Stock Still a Buy After Strong Earnings?

Hims & Hers Health, Inc. (HIMS) Q4 2023 Earnings Call Transcript

Shares of Hims & Hers Health Inc. rallied after hours on Monday, after the online wellness platform said 2024 would be its first year of positive net income and forecast first-quarter and full-year sales that were above expectations.

Hims & Hers' stock jumps on hopes of first profitable year, as it floats opportunities in weight loss

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2023 in a shareholder letter that is posted at investors.hims.com. “Our outstanding results in 2023 underscore the power of the Hims & Hers brands and superior execution across the organization,” said Andrew Dudum, co-founder and CEO. “We are continui.

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Hims & Hers Health stock has rallied over 50% since our previous "Strong Buy" article, but the stock may be overextended, and earnings are approaching. The company's subscription model, market opportunity, and undervalued multiple were the main reasons for our original bullish thesis, and remain relevant today. Recent updates show strong revenue growth, improving economics, and continued execution of a successful land & expand strategy, but the stock's performance may be reflecting these positives.

Hims & Hers: Turning The Profitability Corner And Returning 28%

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced Dan Kenger will join the company's executive team as the first Chief Design Officer. Kenger currently serves as the SVP of Design at Hims & Hers and has been at the company since its founding. “I started at Hims & Hers seven years ago with a commitment to deliver a truly thoughtful, accessible, personalized experience to every person who.

Hims & Hers Names Dan Kenger as the Company's First Chief Design Officer

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Monday, February 26, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa.

News for Hims & Hers Health Stock (HIMS)